Leukemia

Article	Citations
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms	1738
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms	1487
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis	180
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey	169
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments	150
Molecular biology of Hodgkin lymphoma	132
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies	125
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma	116
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia	116
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms	106
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leuk	105
Catch me if you can: how AML and its niche escape immunotherapy	99
Therapeutic implications of menin inhibition in acute leukemias	90
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia	89
Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia	85
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9	84
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) In	80
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML	79
NK-/T-cell lymphomas	72
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial	71
The WHO Classification of Haematolymphoid Tumours	70
Base-edited CAR T cells for combinational therapy against T cell malignancies	70
Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia	68
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma	67
Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape	67

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib	66
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study	64
Treatment resistance in diffuse large B-cell lymphoma	63
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views	63
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial	61
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival	61
CXCR4 in Waldenström’s Macroglobulinema: chances and challenges	61
Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)	60
An evidence that SARS-Cov-2/COVID-19 spike protein (SP) damages hematopoietic stem/progenitor cells in the mechanism of pyroptosis in Nlrp3 inflammasome-dependent manner	59
Current challenges and unmet medical needs in myelodysplastic syndromes	59
JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis	59
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA	57
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial	56
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial	55
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL	55
Decrease post-transplant relapse using donor-derived expanded NK-cells	55
Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease	55
Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion	55
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML	55
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations	54
Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations	53
The KMT2A recombinome of acute leukemias in 2023	53
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b	51
Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis	51
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia	51
HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions	51
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT	50
Mortality trends in multiple myeloma after the introduction of novel therapies in the United States	50
Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression	50
High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance	50
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631	50
Germline variants drive myelodysplastic syndrome in young adults	48
Folate metabolism: a re-emerging therapeutic target in haematological cancers	48
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma	48
Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study	47
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial	47
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results	46
Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears	46
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib	46
Clinical relevance of extracellular vesicles in hematological neoplasms: from liquid biopsy to cell biopsy	46
Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia	44
The mutagenic impact of melphalan in multiple myeloma	44
Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy	43
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations	43
Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia	43
Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of th	42
Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group	41
JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views	41
Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL	41
Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas	40

Current status and future perspectives in targeted therapy of NPM1-mutated AML	40
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial	40
Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms	39
Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma	39
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial	39
Two decades of targeted therapies in acute myeloid leukemia	38
Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia	38
The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma	37
AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome	37
Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease	37
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19	36
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis	36
Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer	36
Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy	36
Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection	36
A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis	36
Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia	35
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis	35
Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets	34
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms	34
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients	34
METTL3 mediates chemoresistance by enhancing AML homing and engraftment via ITGA4	34
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma	33
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia	33
Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study	33
Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence	33
Pediatric MDS and bone marrow failure-associated germline mutations in SAMD9 and SAMD9L impair multiple pathways in primary hematopoietic cells	33
Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research	33
Inhibition of the m6A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia	32
Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma	32
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries	31
CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study	31
Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL	31
Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia	31
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies	31
Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy	31
RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators	31
Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia	31
EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia	31
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial	31
Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease	31
Regulatory T cells promote the stemness of leukemia stem cells through IL10 cytokine-related signaling pathway	30
A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas	30
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis	30
IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells	30
Selective elimination of immunosuppressive T cells in patients with multiple myeloma	30
Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions	30
Whole genome sequencing provides comprehensive genetic testing in childhood B-cell acute lymphoblastic leukaemia	29
Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia	29
Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis	29
APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations	29
Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo	29
MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance	29
Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study	29
EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia	28
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study	28
Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death	28
Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial	28
CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity	28
Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic l	28
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies	28
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines	28
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1	27
CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells	27
Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms	27
Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis	27
Clonal hematopoiesis and its emerging effects on cellular therapies	27
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)	27
Loss of Y and clonal hematopoiesis in blood—two sides of the same coin?	27
Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients	27
TET3 promotes AML growth and epigenetically regulates glucose metabolism and leukemic stem cell associated pathways	27
Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia	26
SARS-CoV-2 antibody responses in patients with acute leukaemia	26
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma	26
Molecular profiling of EBV associated diffuse large B-cell lymphoma	26
Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma	26
Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression	26
Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic	26
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY	26
Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial	26

Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice	25
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML	25
Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting	25
SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia	25
AML classification in the year 2023: How to avoid a Babylonian confusion of languages	25
RNA methylation in hematological malignancies and its interactions with other epigenetic modifications	25
Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia	24
Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia	24
PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression	24
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML	24
STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation	24
DPP4+ exosomes in AML patients’ plasma suppress proliferation of hematopoietic progenitor cells	24
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease	24
Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia	24
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease	24
Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European	24
miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia	24
GSK-3: a multifaceted player in acute leukemias	24
The RNA-binding protein IGF2BP3 is critical for MLL-AF4-mediated leukemogenesis	24
U2af1 is required for survival and function of hematopoietic stem/progenitor cells	24
Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data	24
Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients	24
Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration	24
Clinical and biological aspects of myeloid leukemia in Down syndrome	23
Increased Incidence of IKZF1 deletions and IGH-CRLF2 translocations in B-ALL of Hispanic/Latino children—a novel health disparity	23
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations	23
Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia	22
A modular and controllable T cell therapy platform for acute myeloid leukemia	22
Can we prevent childhood Leukaemia?	22
High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL)	22
Metabolic alterations mediated by STAT3 promotes drug persistence in CML	22
Lysosomes in acute myeloid leukemia: potential therapeutic targets?	22
Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field	22
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial	22
Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin’s lymphomas	22
A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma	22
Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML	22
Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia	22
JunB is a key regulator of multiple myeloma bone marrow angiogenesis	22
Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin	22
Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study	21
YBX1 mediates translation of oncogenic transcripts to control cell competition in AML	21
Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy	21
Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update	21
A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma	21
Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?	21
Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia	21
Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma	21
Molecular landscape of immune pressure and escape in aplastic anemia	21
Biological drivers of clinical phenotype in myelofibrosis	21
Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma	21
RNAseqCNV: analysis of large-scale copy number variations from RNA-seq data	21
DDX41 coordinates RNA splicing and transcriptional elongation to prevent DNA replication stress in hematopoietic cells	21
Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction	20
Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms	20
Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li–Fraumeni syndrome	20
The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival	20
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia	20
Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms	20
Normal life expectancy for polycythemia vera (PV) patients is possible	20
Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia	20
Chronic myelomonocytic leukemia diagnosis and management	20
A comprehensive review of the impact of obesity on plasma cell disorders	20
Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies	20
Asxl1 C-terminal mutation perturbs neutrophil differentiation in zebrafish	20
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia	19
Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape	19
Hematopoiesis and innate immunity: an inseparable couple for good and bad times, bound together by an hormetic relationship	19
Targeting RNA-binding proteins in acute and chronic leukemia	19
Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma	19
CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia	19
Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression	19
Thyroid MALT lymphoma: self-harm to gain potential T-cell help	19
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study	19
Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders	19
Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study	18
Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells	18
Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia	18
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia	18
Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation	18
SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis	18
Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target	18
Germline POT1 variants can predispose to myeloid and lymphoid neoplasms	18
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma	18
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy	18
Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials	18
Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells	18
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies an	18
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from th	18
Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT	18
Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia	18
Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis	18
Changing causes of death in persons with haematological cancers 1975–2016	18
The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH)	17
MiRNA-363-3p/DUSP10/JNK axis mediates chemoresistance by enhancing DNA damage repair in diffuse large B-cell lymphoma	17